Showing 11-20 of 625 results for "".
INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
https://practicalneurology.com/diseases-diagnoses/movement-disorders/intrepid-subthalamic-nucleus-deep-brain-stimulation-parkinson-disease/48741/Jerrold L. Vitek, MD, PhD, Head of the Neurology Department at the University of Minnesota, Minneapolis, MN, provides an overview of the INTREPID clinical trial which assessed subthalamic nucleus deep brain stimulation in patients with Parkinson disease.How to Communicate the Results of Alzheimer Disease Biomarker Tests with Patients
https://practicalneurology.com/videos/neurology-in-motion/how-to-communicate-the-results-of-alzheimer-disease-biomarker-tests-with-patients/39733/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses how to communicate the results of Alzheimer disease biomarker tests with patients.Factors Influencing the Selection of Blood Tests for Alzheimer Disease
https://practicalneurology.com/videos/neurology-in-motion/factors-influencing-the-selection-of-blood-tests-for-alzheimer-disease/39224/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses key factors influencing the selection of blood tests for Alzheimer disease.Seeking Breakthroughs: The Industry Perspective
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/the-industry-perspective/30192/A roundtable discussion with Gregory Went, PhD, Adamas Pharmaceuticals; Lynn Kramer, MD, Eisai; Paulo Fontoura, MD, PhD, Genentech/Roche; Justin Gover, BSc, MBA, GW Pharmaceuticals; Marc Kamin, MD, SK Life Sciences; and Mike Davis, BSc, MBA, UCB- Editorial Board & Contributorshttps://practicalneurology.com/columns/practice-management/editorial-board-contributors/31058/The January 2008 issue of *Practical Neurology* features a distinguished editorial board and contributor lineup, underscoring the journal’s commitment to advancing neurological medicine. Led by Dr. Stephen Gollomp, Chief of Neurology at Lankenau Hospital and Clinical Professor at Thomas Jefferson Un
- Editorial Board & Contributorshttps://practicalneurology.com/columns/practice-management/editorial-board-contributors/31089/The November 2007 issue of Practical Neurology features a distinguished editorial leadership and a diverse panel of contributors dedicated to advancing neurological medicine. Chief Medical Editor Dr. Stephen Gollomp, Chief of Neurology at Lankenau Hospital and Clinical Professor at Thomas Jefferson
- Grand Rounds: Test Your MS Aptitudehttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN1105MSGrandRounds-pdf/31377/Challenging Multiple Sclerosis Diagnoses Explored in Practical Neurology’s November 2005 EditionIn the November 2005 issue of Practical Neurology, Dr. Thomas Leist presents four intricate case studies that delve into the complexities of diagnosing multiple sclerosis (MS) when presentations deviate f
An Update on the Management of Chronic Migraine
https://practicalneurology.com/diseases-diagnoses/headache-pain/an-update-on-the-management-of-chronic-migraine/30697/In 1672, Thomas Willis provided the first description of chronic migraine (CM) when he reported the case of the philosopher, Anne, Viscountess Conway, who was also treated by William Harvey and Robert Boyle without success.1-4 Has our treatment of chronic migraine since improved?SMA Experience: Episode 2
https://practicalneurology.com/diseases-diagnoses/neuromuscular/sma-experience-episode-2/30081/Neuromusclar disease expert Diana Bharucha-Goebel, MD, PhD chats with Traci High, mother of two patients with SMA about how the SMA treatment landscape, and her childens' lives, have changed over the past 15 years.The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/the-impact-of-high-efficacy-dmts-on-paramagnetic-rim-lesions/35439/Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated that high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progressi